A meaningful update to US cosmetics regulations has been a long time coming.
Since the Federal Food, Drug and Cosmetic Act’s enactment in 1938, there’s been no significant reform like the Modernization of...
PCPC Senior Leaders Discuss Historic 2022 And What’s To Come In New Cosmetics Regulatory Era
Listen to this article
HBW Insight spoke with the Personal Care Products Council’s Karin Ross, executive VP of government affairs, and Tom Myers, executive vice president for legal and regulatory affairs and general counsel, to discuss the Modernization of Cosmetic Regulations Act and PCPC’s role to support members’ compliance going forward.
Explore how consumer health is evolving. On the go.
More from Legislation
- • By
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
- • By
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
- • By
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
- • By
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
More from Policy & Regulation
- • By
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
- • By
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
- • By
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.